



16 May 2022

LungLife AI, Inc.
("LungLife" or the "Company")

Block Listing Six Monthly Return

LungLife AI (AIM: LLA1), a developer of clinical diagnostic solutions for lung cancer, makes the following six monthly update on its block listing pursuant to AIM Rule 29 and Schedule 6 of the AIM Rules for Companies:

Name of applicant:		LungLife AI, Inc.		
Name of scheme:		<ol style="list-style-type: none"> 1. 2010 Stock Incentive Plan 2. 2020 Stock Incentive Plan 3. 2021 Omnibus Long-Term Incentive Plan 		
Number and class of securities originally admitted:		1,356,139 common shares of US \$0.0001 each		
Date of admission:		15 November 2021		
Period of return:	From:	15 November 2021	To:	15 May 2022
Balance of unallotted securities under scheme(s) from previous return:		<ol style="list-style-type: none"> 1. 480,775 2. 201,374 3. 673,990 		
<u>Plus:</u> The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):		<ol style="list-style-type: none"> 1. NIL 2. NIL 3. NIL 		
<u>Less:</u> Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):		<ol style="list-style-type: none"> 1. NIL 2. NIL 3. NIL 		
<u>Equals:</u> Balance under scheme(s) not yet issued/allotted at end of period:		<ol style="list-style-type: none"> 1. 480,775 2. 201,374 3. 673,990 		
Total number of securities in issue at the end of the period		25,480,790		

Name of contact:	David Anderson, Chief Financial Officer
Telephone number of contact:	+44 (0)20 7933 8780 or lunglifeai@walbrookpr.com

For further information please contact:

LungLife AI, Inc.

Paul Pagano, CEO
David Anderson, CFO

www.lunglifeai.com

Via Walbrook PR

Investec Bank plc (Nominated Adviser & Broker)

Daniel Adams / Virginia Bull / Cameron MacRitchie

Tel: +44 (0)20 7597 5970

Walbrook PR Limited

Paul McManus / Alice Woodings

Tel: +44 (0)20 7933 8780

or LungLifeAI@walbrookpr.com

Mob: 07980 541 893 / 07407 804 654